(Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been ...

I was trying to find ways of being able to be out of the house and feel good; I didn’t want to feel like people were looking ...